CNS ADVERSE EVENTS ASSOCIATED WITH ANTIMALARIAL AGENTS - FACT OR FICTION

被引:116
作者
PHILLIPSHOWARD, PA
TERKUILE, FO
机构
[1] Malaria Unit, Division of Control of Tropical Diseases, World Health Organization, Geneva
[2] Unit of Infectious Diseases, AIDS and Tropical Medicine, Academic Medical Centre, Amsterdam, 1105 AZ, F4-222
关键词
D O I
10.2165/00002018-199512060-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
CNS adverse drug events are dramatic, and case reports have influenced clinical opinion on the use of antimalarials. Malaria also causes CNS symptoms, thus establishing causality is difficult. CNS events are associated with the quinoline and artemisinin derivatives. Chloroquine, once considered too toxic for humans, has been the antimalarial of choice for 40 years. While a range of serious CNS effects have been documented during chloroquine therapy, the incidence is unclear (extrapyramidal symptoms occur with an incidence of 1 in 5000). Amodiaquine has a higher incidence of mild CNS effects than chloroquine. Mefloquine therapy causes dose-related transient dizziness. Serious CNS events during mefloquine therapy occur in 1 : 1200 Asians and 1 : 200 Caucasians/Africans. Risk factors include dosage, concomitant drug use/interactions, previous history of a CNS event and disease severity. Retreatment (within a month) increases the risk in Asians 7-fold. Studies indicate that the frequency of serious CNS events with mefloquine prophylaxis (1 : 10 000) is similar to that with chloroquine (1 : 13 600). Quinine causes cinchonism at standard therapeutic doses. High-tone hearing loss occurs, but irreversible auditory or ocular effects are very rare. The artemisinin derivatives are associated with dose-dependent brain lesions in rodent, canine and nonhuman primates. At low doses, histological injury has been demonstrated, without clinical neurological signs. No significant toxicity has been reported in humans. Other antimalarial drugs are seldom associated with CNS adverse events. Data do not suggest a need to diminish the correct use of the quinoline derivatives. Irreversible effects are extremely rare and usually associated with overdosing or prior history of a serious CNS event. Concomitant therapeutic use of 2 drugs from the same family, or retreatment with the same drug, should be avoided. Onset of drug-associated serious CNS events requires drug discontinuation and future avoidance of the drug.
引用
收藏
页码:370 / 383
页数:14
相关论文
共 73 条
  • [1] The role of artemisinin and its derivatives in the current treatment of malaria (1994–1995), (1994)
  • [2] Jaeger A., Sauder P., Kopferschmitt J., Et al., Clinical features and management of poisoning due to antimalarial drugs, Med Toxicol, 2, (1987)
  • [3] Coatney G.R., Pitfalls in a discovery: the chronicle of chloroquine, Am J Trop Med Hyg, 12, (1963)
  • [4] Frisk Holmberg M., Bergqvist Y., Domeij-Niberg B., Et al., Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics, Clin Pharmacol Ther, 25, (1979)
  • [5] Steffen R., Fuchs E., Schildknecht J., Et al., Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa, Lancet, 341, (1993)
  • [6] Lobel H.O., Miani M., Eng T., Et al., Long-term malaria prophylaxis with weekly mefloquine, Lancet, 341, (1993)
  • [7] Mohan D., Mohandas E., Rajat R., Chloroquine psychosis: a chemical psychosis, J Natl Med Assoc, 73, (1981)
  • [8] Ragan E., Wilson R., Li F., Et al., Psychotic symptoms in volunteers serving overseas, Lancet, 2, (1985)
  • [9] Umez-Eronini E.M., Eronini E.A., Chloroquine induced involuntary movements, BMJ, 1, (1977)
  • [10] Singh R.P.N., Sinha A.K.N., Neuropsychiatric toxicity of chloroquine, J Indian Med Assoc, 77, (1981)